Author

G. Zoppoli

Listed by name: these papers carry no ORCID for this author, so different people with the same name may be mixed together.

Biology Disciplines

Click to filter author papers

Cancer Biology· 3 Immunology· 3

Signature Assays, Organisms & Methods

Click to filter · or open tag

Assay:bulk RNA-seq· 6 Organism:human· 6 Research Focus:cell type annotation· 4 Research Focus:differential expression· 3 Approach:statistical model· 3 Approach:biophysical modeling· 1 Research Focus:drug response / drug discovery· 1 Approach:experimental assay· 1

Frequent Co-Authors

D. Bedognetti· 6 shared A. Ballestrero· 4 shared D. Rinchai· 4 shared D. Chaussabel· 3 shared B. Cigolini· 2 shared B. Tang· 2 shared G. Gentilcore· 2 shared J. Decock· 2 shared

Activity by Year

2019-2024 · peak 2/yr

Co-Author Collaboration Network

10 top collaborators · 37 mutual co-author links

Click any collaborator node to inspect or filter shared papers

Focal author (center)Selected co-authorORCID co-authorUnlinked name

Curved chords = mutual co-authorship

6 shared papersImmunology

D. Bedognetti

Mutual co-authors in cluster

Author profile →

6 papers

Recent·Most cited

Biological modifications of the immune response to COVID-19 vaccine in patients treated with rituximab and immune-checkpoint inhibitors

F. Ravera, M. Dameri, I. Lombardo, M. Stabile, N. Fallani, C. Scarsi, B. Cigolini, G. Gentilcore, A. Domnich, L. Zullo, E. Cella, G. Francia, E. Montanari, A. Orsi, A. Bellodi, , G. Zoppoli

This study examines how rituximab and immune-checkpoint inhibitors affect immune responses to a COVID-19 booster vaccine, finding rituximab impairs interferon response and ICI maintains normal immune profiles.

bioRxiv · Mar 5, 2024Immunology

Modulation of SLFN11 induces changes in DNA Damage response

C. M. Raynaud, E. I. Ahmed, A. Jabeen, A. Sanchez, S. Sherif, T. C. Carneiro-Lobo, A. Awad, D. Awartani, A. Naik, R. Thomas, J. Decock, G. Zoppoli, D. Bedognetti, W. Hendrickx

This study shows that increasing SLFN11 expression through CRISPR-dCas9 systems enhances DNA damage response sensitivity in breast cancer cells.

bioRxiv · Apr 2, 2023 · PreprintCancer Biology

High temporal resolution systems profiling reveals distinct patterns of interferon response after Covid-19 mRNA vaccination and SARS-CoV2 infection

D. Rinchai, S. Deola, G. Zoppoli, B. S. A. Kabeer, S. A. Taleb, I. Pavlovski, S. Maacha, G. Gentilcore, M. Toufiq, L. Matthew, L. Liu, F. R. Vempalli, G. Mubarak, S. Lorenz, I. Sivieri, , D. Chaussabel

This study uses high-temporal-resolution transcriptome profiling to compare interferon responses after mRNA vaccination and SARS-CoV-2 infection, identifying distinct signatures linked to immune outcomes.

bioRxiv · Dec 12, 2021 · PreprintImmunology

SLFN11 captures cancer-immunity interactions associated with platinum sensitivity in ovarian cancer

C. Winkler, D. Ferraioli, A. Garuti, F. Grillo, J. Rodriguez-Canales, L. Ferrando, N. Chopin, I. Ray-Coquard, D. Bedognetti, A. Ballestrero, E. Leo, G. Zoppoli

The paper quantifies SLFN11 in ovarian cancer tissues and shows its expression in immune cells, linking it to favorable outcomes and cancer-immunity interactions related to platinum sensitivity.

bioRxiv · May 22, 2020Cancer Biology

A modular framework for the development of targeted Covid-19 blood transcript profiling panels

D. Rinchai, B. Kabeer, M. Toufiq, Z. Calderone, S. Deola, T. Brummaier, M. Garand, R. Branco, N. Baldwin, M. Alfaki, M. Altman, A. Ballestrero, M. Bassetti, G. Zoppoli, A. De Maria, , D. Chaussabel

The paper develops a modular framework for designing targeted blood transcript profiling panels to study the immune response to SARS-CoV-2 infection.

bioRxiv · May 20, 2020Immunology

Genomic landscape of tumor-host interactions with differential prognostic and predictive connotations

J. Roelands, W. Hendrickx, P. J. K. Kuppen, R. Mall, G. Zoppoli, M. Saad, K. Halliwill, G. Curigliano, D. Rinchai, J. Decock, L. Delogu, T. Turan, J. Samayoa, L. Chouchane, E. Wang, , D. Bedognetti

The paper analyzes tumor-host interactions across 31 cancer types using the ICR signature to identify prognostic and predictive implications of immune phenotypes.

bioRxiv · May 8, 2019Cancer Biology